We are a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets we serve through the development, manufacture and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
- 17-Mar-2010
- » Hikma’s diversified business delivers record sales and 36% earnings growth in 2009
- 17 March 2010 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ DUBAI: HIK), the fast growing multinational pharmaceutical group, today reports its preliminary results for the year ended 31 December 2009.
- 01-Mar-2010
- » Hikma will release its 2009 preliminary results on Wednesday, March 17, 2010
- LONDON, 1 March 2010 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (Nasdaq Dubai: HIK), the fast growing multinational pharmaceutical Group, will release its 2009 preliminary results on Wednesday, 17 March 2010. The company will host a presentation for analysts at 9 am and a live webcast of the presentation will be available on Hikma’s website. www.hikma.com
